Dr. Geng focuses his practice on various patent prosecution and patent litigation areas, and more specifically on US and foreign patent prosecution, due diligence, prior art and patentability search, freedom to operate analysis, inter partes review and patent litigation. Dr. Geng has helped a variety of startup, mid-size and well-established clients in the life sciences sector, including chemical, pharmaceutical, biotechnology, and energy industries, to obtain patent protection in the US and foreign countries. Dr. Geng's practice focus also includes Hatch-Waxman and other patent litigations for leading pharmaceutical companies.

Prior to joining the firm, Dr. Geng was a Research Investigator at the Novartis Institute for Biomedical Research in Cambridge, Massachusetts. His primary research involved discovering drug-like molecules that modulated protein targets and pathways implicated in diabetes and metabolic diseases.

From 2002 to 2004, Dr. Geng was a US Army Breast Cancer Research Foundation Postdoctoral Fellow in Dr. Samuel Danishefsky's laboratory at the Memorial Sloan-Kettering Cancer Center in New York, where he accomplished the total synthesis of anticancer agent aigialomycin D and worked as a part of a team to design and accomplish the total synthesis of fully synthetic gp120 glycopeptides as anti-HIV vaccine agents.

Dr. Geng obtained his PhD degree from State University of New York at Stony Brook in 2002, where he designed and synthesized taxoid and taxane-free anticancer agents in Professor Iwao Ojima's laboratories.

Selected Journal Publications and Patents

• Ojima, I. et al., “Design, synthesis, and biological evaluation of new-generation taxoids,” Journal of Medicinal Chemistry, 2008, 51, 3203-3221.
• Krauss, I. J. et al, “Fully synthetic carbohydrate HIV antigens designed on the logic of the 2G12 antibody,” Journal of the American Chemical Society, 2007, 129, 11042-11044.
• Warren, J.D.; Geng, X.; Danishefsky, S. J., “Synthetic glycopeptides-based vaccines,” Topics in Current Chemistry 2007, 267 (Glycopeptides and Glycoproteins), 109-141.
• Geng, X.; Danishefsky, S. J. “Total synthesis of aigialomycin D”, Organic Letters 2004, 6, 413-416.
• Geng, X., Yang, Z.-Q., Danishefsky, S. J. “Synthetic development of radicicol and cycloproparadicicol: highly promising anticancer agents targeting Hsp90”, Synlett 2004, 8, 1325-1333.
• Geng, X.; Dudkin, V. Y.; Mandal, M.; Danishefsky, S. J. “Glycopeptides (2): In pursuit of carbohydrate-based HIV vaccines, Part 2: the total synthesis of high-mannose-type gp120 fragments-evaluation of strategies directed to maximal convergence”, Angewandte Chemie International Edition 2004, 43, 2562-2565.
• Geng, X.; Geney, R.; Pera, P.; Bernacki, R. J.; Ojima, I. “Design and synthesis of de novo cytotoxic alkaloids through mimicking taxoid skeleton”, Bioorganic Medicinal Chemistry Letters 2004, 14, 3491-3494.
• Geng, X.; Miller, M. L.; Lin, S.; Ojima, I. “Synthesis of novel C2-C3'N-linked macrocyclic taxoids by means of highly regioselective heck macrocyclization”, Organic Letters 2003, 5, 3733-3736.
• Danishefsky, S. J.; Dudkin, V.; Geng, X.; Mandal, M.; Kraus, I., Gp120 specific antigen and uses thereof, US Patent No. 7,531,181.
• Danishefsky, S. J.; Dudkin, V.; Geng, X.; Mandal, M.; Olson, W.; Orlova, M., Preparation of gp120 glycopeptide dimers for treatment of HIV-1, 2006, WO 2006017180.
• Danishefsky, S. J.; Yang, Z.-Q.; Geng, X.; Chou, T.-C.; Rosen, N., Preparation of aigialomycin D, radicicol and monocillin I and their macrocyclic analogs for use in pharmaceutical compositions as antitumor agents, 2005, WO 2005061481.
• Danishefsky, S. J.; Dudkin, V.; Geng, X.; Mandal, M., Glycopeptide gp120 specific antigens, conjugates thereof, methods for their preparation and uses thereof, 2004, WO 2004050711.

Professional Activities